Related Experiment Videos
[Meningococcal disease in Africa--epidemiology and prevention]
G Norheim1, E Rosenqvist, P Aavitsland
1Avdeling for vaksine, Statens institutt for folkehelse, Oslo.
Abstract:
Neisseria meningitidis is one of the most common causes of purulent meningitis all over the world. Large epidemics caused by meningococci have spread during the last decade throughout vast areas of Africa, also outside the region referred to as the classic "Meningitis Belt". Globally, this organism each year causes about 300,000 cases and 30,000 deaths; most of these are children. Meningococci of serogroup A cause a major part of these epidemics, and a remarkable feature of the epidemical situation is that the bacteria differ very little in antigenic properties as they belong to the same clonal group of meningococci. Immunization with safe and effective vaccines is the most efficient way of combatting these epidemics. The currently available polysaccharide vaccines against serogroup. A meningococcal disease do not induce long-term immunological memory and do not provide adequate protection of children below two years of age. There is an urgent need for a vaccine that induces long-term immunological memory in all age groups, so it can be included in the routine vaccination program. In contrast to serogroup C, the development of conjugate vaccines against serogroup A meningococcal disease has not yielded the positive results hoped for. The development of alternative protein-based vaccines therefore needs to be intensified.
Insights
Neisseria meningitidis causes widespread meningitis epidemics, particularly in Africa. Current vaccines are insufficient for young children, highlighting the need for new protein-based vaccines to induce long-term immunity.
Area of Science:
- Microbiology
- Epidemiology
- Vaccinology
Background:
- Neisseria meningitidis is a leading cause of bacterial meningitis globally, responsible for significant mortality, especially among children.
- Epidemics of meningococcal disease, primarily caused by serogroup A, continue to impact Africa and beyond.
- Existing polysaccharide vaccines for serogroup A lack long-term efficacy in children under two and fail to establish immunological memory.
Purpose of the Study:
- To address the limitations of current meningococcal vaccines.
- To emphasize the urgent need for novel vaccines against serogroup A meningococcal disease.
- To advocate for the intensification of research into alternative protein-based vaccines.
Main Methods:
- Review of current epidemiological data on Neisseria meningitidis outbreaks.
- Analysis of the immunological properties and limitations of existing polysaccharide and conjugate vaccines.
- Assessment of the potential for developing new vaccine strategies.
Main Results:
- Serogroup A Neisseria meningitidis remains a significant threat, causing substantial global morbidity and mortality.
- Current vaccines do not provide adequate protection for vulnerable populations, particularly young children.
- Development of conjugate vaccines against serogroup A has faced challenges.
Conclusions:
- There is a critical need for vaccines that induce long-term immunity across all age groups for serogroup A meningococcal disease.
- Protein-based vaccine development requires increased focus and resources.
- Effective vaccination strategies are essential to combat devastating meningococcal epidemics.